Developer docs
API playgroundTry for free, no card

Search company profiles

Sequenom

Full company profile

uuid002zv8t

Namestring
Sequenom
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Sequenom was a San Diego-based molecular diagnostics company founded in 1994 that developed and commercialized non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) analysis from maternal blood samples. Its core technology detected chromosomal abnormalities — primarily trisomy 21 (Down syndrome), trisomy 18, and trisomy 13 — from a simple maternal blood draw as early as 9-10 weeks gestation, eliminating the miscarriage risk associated with invasive diagnostic procedures such as amniocentesis and chorionic villus sampling. The company was recognized in third-party market research as a pioneer and key player in the NIPT market, competing with Illumina, Natera, Roche, Guardant Health, Myriad Genetics, and Verinata Health.

The company's revenue model was clinical laboratory services: Sequenom operated CLIA-certified laboratories and generated revenue from billable NIPT tests ordered by obstetricians, maternal-fetal medicine specialists, and genetic counselors for their patients. Go-to-market was sales-led, targeting healthcare providers and health systems through clinical sales channels and integration into routine prenatal care workflows. Marketing relied on industry conferences, medical publications, and inclusion in market research reports identifying it as a leading NIPT player.

Sequenom's corporate trajectory ended its independent operations through successive acquisitions: the company was acquired by Invitae in 2018, and Invitae's reproductive health assets (including Sequenom) were subsequently acquired by Natera in January 2024 for $42.5 million. Sequenom's former website (sequenom.com) now redirects to Labcorp Women's Health, suggesting further brand or asset migration. Sequenom raised over $185 million in disclosed funding rounds, with its largest raise being a $130 million round in September 2012 during the peak of NIPT commercial expansion.

Short descriptiontext

Sequenom was a San Diego-based molecular diagnostics company that developed non-invasive prenatal testing (NIPT) using cell-free DNA analysis from maternal blood to screen for chromosomal abnormalities. The company was acquired by Invitae in 2018 and then by Natera in 2024.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWestborough, United States
HQ citystring
Westborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
non-invasive prenatal testing, cell-free DNA analysis, prenatal genetic screening, trisomy detection, maternal blood testing
Industry3 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Prenatal Genetic Diagnostics / Clinical Laboratory Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1NIPT Laboratory Services
TypeProfessional Services
Description

Sequenom generates revenue through the provision of non-invasive prenatal testing laboratory services to healthcare providers and patients. The company operates within the broader non-invasive prenatal testing market, which is projected to reach $12.37 billion by 2030, growing at a CAGR of 14.4%. Revenue is derived from billable clinical laboratory tests performed on maternal blood samples.

openpr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sequenom operates as a clinical laboratory services provider specializing in non-invasive prenatal testing (NIPT). The company performs cell-free DNA (cfDNA) analysis on maternal blood samples to screen for chromosomal abnormalities including trisomy 21 (Down syndrome), trisomy 18, and trisomy 13, offering a safer alternative to invasive diagnostic procedures such as amniocentesis and CVS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Non-invasive prenatal testing market projected to reach $12.37 billion by 2030 at 14.4% CAGR
Product overview1 text field

Sequenom is identified as a key market player in the non-invasive prenatal testing (NIPT) and noninvasive prenatal gene testing technology market. Based on market research reports, Sequenom operates in the reproductive health and genetic testing sector, competing with companies such as Illumina, Natera, Roche, Guardant Health, Aria Diagnostics, Fulgent Genetics, Myriad Genetics, and Verinata Health. However, detailed product portfolio information for Sequenom is not available in the provided source data.

Product and service1 record
1Non-invasive Prenatal Testing (NIPT) Laboratory Services
CategoryPrenatal Genetic Diagnostics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Quest Diagnostics is a major reference laboratory offering QNatal Advanced NIPT and a broad women's health test menu. As a comparable clinical laboratory services provider serving obstetricians, it competes with Sequenom in the same provider-order workflow.

TypeDirect peer
Description

Illumina acquired Verinata Health and offers the Verifi NIPT test. As a leading sequencing platform provider and NIPT competitor, Illumina competes with Sequenom at both the laboratory services and upstream technology levels.

TypeDirect peer
Description

Natera is a direct competitor in NIPT (Panorama) and acquired Sequenom's reproductive health assets in January 2024 for $42.5M. It offers a comparable cfDNA-based NIPT service to obstetricians and maternal-fetal medicine specialists, making it the closest direct peer.

TypeEmerging player
Description

Fulgent Genetics is a genetic testing laboratory offering reproductive and hereditary cancer tests. While smaller than the major NIPT players, it provides comparable cfDNA-based NIPT services and is identified as a market competitor alongside Sequenom.

TypeBroad incumbent
Description

Myriad Genetics is a broader women's health and genetic testing company offering prenatal screening, hereditary cancer testing, and other molecular diagnostics. It competes with Sequenom in reproductive genetics while also operating in adjacent genetic testing categories.

TypeBroad incumbent
Description

Labcorp is a major reference laboratory currently hosting the Sequenom brand under its Women's Health division (womenshealth.labcorp.com). It competes broadly in clinical laboratory services and has the infrastructure to deliver NIPT at scale.

TypeOthers
Description

Guardant Health is identified as a market competitor alongside Sequenom in industry market research. While primarily focused on oncology liquid biopsy, its cfDNA expertise creates technology overlap with NIPT and positions it as an adjacent genomic diagnostics player.

TypeBroad incumbent
Description

Invitae acquired Sequenom in 2018 and operated it within its reproductive health business before divesting the assets to Natera in 2024. It remains a comparable genetic testing laboratory competing in reproductive and hereditary cancer testing.

TypeEmerging player
Description

BillionToOne offers the UNITY Screen, a non-invasive prenatal screen that combines cfDNA analysis with cell-free fetal fraction quantification. As an emerging specialty NIPT competitor, it is increasingly cited alongside traditional players like Sequenom in the NIPT market.

TypeDirect peer
Description

Roche offers the Harmony Prenatal Test through its Ariosa Diagnostics subsidiary. As a major diversified diagnostics player, Roche competes with Sequenom across global NIPT markets and has substantially larger commercial and reimbursement infrastructure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sequenom

Prenatal Genetic Diagnostics / Clinical Laboratory Serviceswomenshealth.labcorp.com

Sequenom was a San Diego-based molecular diagnostics company that developed non-invasive prenatal testing (NIPT) using cell-free DNA analysis from maternal blood to screen for chromosomal abnormalities. The company was acquired by Invitae in 2018 and then by Natera in 2024.

What Sequenom does

Sequenom was a San Diego-based molecular diagnostics company founded in 1994 that developed and commercialized non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) analysis from maternal blood samples. Its core technology detected chromosomal abnormalities — primarily trisomy 21 (Down syndrome), trisomy 18, and trisomy 13 — from a simple maternal blood draw as early as 9-10 weeks gestation, eliminating the miscarriage risk associated with invasive diagnostic procedures such as amniocentesis and chorionic villus sampling. The company was recognized in third-party market research as a pioneer and key player in the NIPT market, competing with Illumina, Natera, Roche, Guardant Health, Myriad Genetics, and Verinata Health.

The company's revenue model was clinical laboratory services: Sequenom operated CLIA-certified laboratories and generated revenue from billable NIPT tests ordered by obstetricians, maternal-fetal medicine specialists, and genetic counselors for their patients. Go-to-market was sales-led, targeting healthcare providers and health systems through clinical sales channels and integration into routine prenatal care workflows. Marketing relied on industry conferences, medical publications, and inclusion in market research reports identifying it as a leading NIPT player.

Sequenom's corporate trajectory ended its independent operations through successive acquisitions: the company was acquired by Invitae in 2018, and Invitae's reproductive health assets (including Sequenom) were subsequently acquired by Natera in January 2024 for $42.5 million. Sequenom's former website (sequenom.com) now redirects to Labcorp Women's Health, suggesting further brand or asset migration. Sequenom raised over $185 million in disclosed funding rounds, with its largest raise being a $130 million round in September 2012 during the peak of NIPT commercial expansion.

Sequenom firmographics

Firmographics
Name
Sequenom
Website
https://womenshealth.labcorp.com
Company type
Private
Founded year
1994
Headcount range
101–250 employees
Short description
Sequenom was a San Diego-based molecular diagnostics company that developed non-invasive prenatal testing (NIPT) using cell-free DNA analysis from maternal blood to screen for chromosomal abnormalities. The company was acquired by Invitae in 2018 and then by Natera in 2024.
Ownership category
akta.pro rank

Sequenom industry classification

Industry
Product category
Prenatal Genetic Diagnostics / Clinical Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories

Keywords

  • Non-invasive prenatal testing
  • Cell-free DNA analysis
  • Prenatal genetic screening
  • Trisomy detection
  • Maternal blood testing

Where Sequenom is headquartered

Location

Headquarters

HQ city
Westborough
HQ country
United States
HQ region
North America

Markets served

Sequenom business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. NIPT Laboratory Services: Sequenom generates revenue through the provision of non-invasive prenatal testing laboratory services to healthcare providers and patients. The company operates within the broader non-invasive prenatal testing market, which is projected to reach $12.37 billion by 2030, growing at a CAGR of 14.4%. Revenue is derived from billable clinical laboratory tests performed on maternal blood samples.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Sequenom product offering

Product offering

Core offering

Sequenom operates as a clinical laboratory services provider specializing in non-invasive prenatal testing (NIPT). The company performs cell-free DNA (cfDNA) analysis on maternal blood samples to screen for chromosomal abnormalities including trisomy 21 (Down syndrome), trisomy 18, and trisomy 13, offering a safer alternative to invasive diagnostic procedures such as amniocentesis and CVS.

Product overview

Sequenom is identified as a key market player in the non-invasive prenatal testing (NIPT) and noninvasive prenatal gene testing technology market. Based on market research reports, Sequenom operates in the reproductive health and genetic testing sector, competing with companies such as Illumina, Natera, Roche, Guardant Health, Aria Diagnostics, Fulgent Genetics, Myriad Genetics, and Verinata Health. However, detailed product portfolio information for Sequenom is not available in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • Non-invasive Prenatal Testing (NIPT) Laboratory Services

Quantifiable outcome

  • Non-invasive prenatal testing market projected to reach $12.37 billion by 2030 at 14.4% CAGR

Companies that use Sequenom

Customer profile

Segments1 record

Ideal customer profiles1 record

Sequenom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Sequenom partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights2 records

Sequenom competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is a major reference laboratory offering QNatal Advanced NIPT and a broad women's health test menu. As a comparable clinical laboratory services provider serving obstetricians, it competes with Sequenom in the same provider-order workflow.
  • Myriad Genetics: Myriad Genetics is a broader women's health and genetic testing company offering prenatal screening, hereditary cancer testing, and other molecular diagnostics. It competes with Sequenom in reproductive genetics while also operating in adjacent genetic testing categories.
  • Labcorp: Labcorp is a major reference laboratory currently hosting the Sequenom brand under its Women's Health division (womenshealth.labcorp.com). It competes broadly in clinical laboratory services and has the infrastructure to deliver NIPT at scale.
  • Invitae: Invitae acquired Sequenom in 2018 and operated it within its reproductive health business before divesting the assets to Natera in 2024. It remains a comparable genetic testing laboratory competing in reproductive and hereditary cancer testing.

Direct peers

  • Illumina: Illumina acquired Verinata Health and offers the Verifi NIPT test. As a leading sequencing platform provider and NIPT competitor, Illumina competes with Sequenom at both the laboratory services and upstream technology levels.
  • Natera: Natera is a direct competitor in NIPT (Panorama) and acquired Sequenom's reproductive health assets in January 2024 for $42.5M. It offers a comparable cfDNA-based NIPT service to obstetricians and maternal-fetal medicine specialists, making it the closest direct peer.
  • Roche: Roche offers the Harmony Prenatal Test through its Ariosa Diagnostics subsidiary. As a major diversified diagnostics player, Roche competes with Sequenom across global NIPT markets and has substantially larger commercial and reimbursement infrastructure.

Emerging players

  • Fulgent Genetics: Fulgent Genetics is a genetic testing laboratory offering reproductive and hereditary cancer tests. While smaller than the major NIPT players, it provides comparable cfDNA-based NIPT services and is identified as a market competitor alongside Sequenom.
  • BillionToOne: BillionToOne offers the UNITY Screen, a non-invasive prenatal screen that combines cfDNA analysis with cell-free fetal fraction quantification. As an emerging specialty NIPT competitor, it is increasingly cited alongside traditional players like Sequenom in the NIPT market.

Others

  • Guardant Health: Guardant Health is identified as a market competitor alongside Sequenom in industry market research. While primarily focused on oncology liquid biopsy, its cfDNA expertise creates technology overlap with NIPT and positions it as an adjacent genomic diagnostics player.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Sequenom social profiles

Digital presence

Sequenom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sequenom leadership team

Management profile

Number of profiles

Profiles4 records

Sequenom funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sequenom M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sequenom

What does Sequenom do?

Sequenom operates as a clinical laboratory services provider specializing in non-invasive prenatal testing (NIPT). The company performs cell-free DNA (cfDNA) analysis on maternal blood samples to screen for chromosomal abnormalities including trisomy 21 (Down syndrome), trisomy 18, and trisomy 13, offering a safer alternative to invasive diagnostic procedures such as amniocentesis and CVS.

When was Sequenom founded?

Sequenom was founded in 1994. It employs 101 to 250 people.

Where is Sequenom based?

Sequenom is headquartered in Westborough, United States, in the North America region.

How does Sequenom make money?

One revenue line is on record: NIPT Laboratory Services.

Who are Sequenom's main competitors?

Broad incumbents on record are Quest Diagnostics, Myriad Genetics, Labcorp and Invitae. Direct peers are Illumina, Natera and Roche. Emerging players are Fulgent Genetics and BillionToOne. Guardant Health is listed as an others.

Does Sequenom have an API?

No public API is recorded for Sequenom.

What industry is Sequenom in?

Sequenom's product category is Prenatal Genetic Diagnostics / Clinical Laboratory Services. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Non-Invasive Prenatal Testing (NIPT) Market Analysis Report 2023-2028: Cell-Free DNA Tests Gain Popularity with Diagnostic Centers Playing Vital Role in Expanding NIPT ServicesResearchAndMarkets.com published a market analysis report projecting the global non-invasive prenatal testing (NIPT) market will grow from US$3.38 billion in 2022 to approximately US$9.37 billion by 2030, representing a compound annual growth rate of 13.6%. The report attributes market expansion to rising prevalence of chromosomal abnormalities, advancements in next-generation sequencing technology, expanding insurance coverage, and increasing adoption of non-invasive fetal diagnostics among both high-risk and low-risk pregnancy segments. Key companies identified as participants in the NIPT market include Natera, Sequenom, Ariosa Diagnostics, Illumina, Thermo Fisher Scientific, Roche, Eurofins Scientific, Revvity, Quest Diagnostics, and Agilent Technologies, with the United States representing the most established market and the Netherlands cited as a country where NIPT has become standard prenatal care.GlobeNewswireGlobal Non-Invasive Prenatal Testing (NIPT) Market Research Report 2023 with Competitive Analysis of Key Players Such as Natera, Sequenom, and Ariosa DiagnosticsThe global non-invasive prenatal testing (NIPT) market was valued at $3.38 billion in 2022 and is projected to reach $9.37 billion by 2030, a CAGR of 13.6%. Growth is driven by expanded insurance coverage, rising genetic abnormality prevalence, and NGS technology advancements. The U.S. leads adoption, with Natera, Sequenom, and Ariosa Diagnostics as key players.GlobeNewswireGlobal Non-Invasive Prenatal Testing (NIPT) Market Research Report 2023 with Competitive Analysis of Key Players Such as Natera, Sequenom, and Ariosa DiagnosticsThe global non-invasive prenatal testing (NIPT) market was valued at US$3.38 billion in 2022 and is projected to reach US$9.37 billion by 2030, a CAGR of 13.6%. Growth is driven by expanded insurance coverage, rising genetic abnormalities, and NGS technology. The US leads adoption, with Natera, Sequenom, and Ariosa Diagnostics as key players.dlvr.itLearn electronics with the Lab-On-The-GoEIM Technology launched the Lab-On-The-Go, an experimental-based learning kit for teaching electronics from the ground up. The kit includes a manual covering 20 circuiting concepts and early-bird pledges are available for roughly $66 or £56. Worldwide shipping is expected around December 2022 if the crowdfunding goal is met.Tech.euUK cyber intelligence outfit Lab 1 draws £1 million to build context knowledge graphs of data breaches.Lab 1, a London-based cyber intelligence startup, raised £1 million to expand its product and business. Its CiGraph platform processes 24 billion data points from web forums and messaging platforms to quantify cyber risk. The funding was led by MMC Ventures, with Alan Morgan investing privately.The VergeGo read this NYT investigation on the inaccuracy of prenatal blood testsThe New York Times reported that noninvasive prenatal testing (NIPT) for rare conditions like Wolf-Hirschhorn and Cri-du-chat syndrome yields false positives 80% or more of the time. The tests, marketed as highly accurate, often lead to expensive invasive follow-up or pregnancy termination, with companies like Natera and Sequenom involved.PR NewswireGlobal Prenatal Diagnostics IndustryReportlinker published a comprehensive market research report analyzing the global prenatal diagnostics industry, covering market size, forecasts, trends, and competitive landscape for the period 2015 through 2022. The report profiles 43 companies including major players such as Illumina, Hologic, Berry Genomics, BGI Genomics, F. Hoffmann-La Roche, and Sequenom, providing regional breakdowns across US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World markets. Key industry trends identified include the growth of non-invasive prenatal testing (NIPT), increasing healthcare spending supporting market expansion, and competitive activity through M&A deals and product approvals among leading players.PR NewswireGlobal Liquid Biopsy Market, 2018-2030: Market is Expected to Reach USD 5.96 Billion - Enhanced View of Tumor Provided by Liquid Biopsy TechnologyResearchAndMarkets.com released a market report projecting the global liquid biopsy market to reach USD 5.96 billion by 2030, growing at a CAGR of 13.4% during the forecast period. The report highlights liquid biopsy technology as a less invasive alternative to traditional tissue biopsies, which are costly and associated with complications. Key companies engaged in R&D and commercialization of liquid biopsy products include Pathway Genomics, Natera Inc., Epic Sciences, Illumina, Foundation Medicine, Roche, LabCorp, Sequenom, and others.IPWatchdog.com6 Years Later: The Effects of the Mayo Decision on Diagnostic Methods - IPWatchdog.comSix years after the Supreme Court's Mayo v. Prometheus decision, diagnostic method patent eligibility remains unclear. The ruling split eligibility into two steps, leading to frequent invalidations of method patents, including Myriad's BRCA patents and Sequenom's prenatal tests. The Court's guidance remains ambiguous, leaving uncertainty for biotech and life science innovations.